A survey of 86 German patient groups suggests pharma’s reputation is improving in the country that has been wary of pharma in the past, with Amgen and Janssen leading the way.
Making sure everyone with DMD gets access to treatments and the ‘essential’ interventions that can make life worth living is key.
Digital health solutions that work in the real world must also be designed to effectively support the patient’s tasks and goals, while being engaging to use. In other words, they need to be built with patients, not for them, say Alex Butler and Gavin Birchnall.
Patient centricity is a priority for Merck and its Executive Vice President and Head of EMEA Region, Chris Round, outlines what practical steps the company is taking to improve life for patients and carers.
Pharma needs a full picture of insights from all stakeholders, including patients, from the earliest stages of the product lifecycle.
